1887

Abstract

Introduction. Enterococcus faecium is a commensal organism commonly colonizing the human gastrointestinal tract. Although it is generally a non-virulent organism, E. faecium can cause significant morbidity and mortality due to its inherent and acquired resistances to commonly used antimicrobials. Patients who are immunosuppressed are particularly vulnerable.

Case presentation. A 65–75-year-old patient with a history of an orthotopic liver transplant for hepatitis C infection and diabetes was re-admitted to the hospital with abdominal pain and fever. The patient had several recent admissions related to the presentation reported here, which included treatment with a prolonged course of broad-spectrum antibiotics. The patient was found to have a recurrent liver abscess and blood cultures grew vancomycin-resistant E. faecium, non-susceptible to all tested agents: ampicillin, penicillin, vancomycin, daptomycin and linezolid. The patient was started initially on chloramphenicol intravenously while awaiting additional susceptibility testing, which ultimately revealed chloramphenicol non-susceptibility. Tigecycline was started but the patient ultimately decided to pursue hospice care.

Conclusion. Multi-drug-resistant organisms are increasingly being recognized and are associated with poorer outcomes, particularly in immunosuppressed patients. We describe a particularly resistant organism and discuss potential therapeutic options.

Loading

Article metrics loading...

/content/journal/jmmcr/10.1099/jmmcr.0.005172
2018-12-20
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmmcr/6/1/jmmcr005172.html?itemId=/content/journal/jmmcr/10.1099/jmmcr.0.005172&mimeType=html&fmt=ahah

References

  1. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012;10:266–278 [CrossRef][PubMed]
    [Google Scholar]
  2. Prematunge C, MacDougall C, Johnstone J, Adomako K, Lam F et al. VRE and VSE bacteremia outcomes in the era of effective vre therapy: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2016;37:26–35 [CrossRef][PubMed]
    [Google Scholar]
  3. Patel G, Snydman DR.AST Infectious Diseases Community of Practice Vancomycin-resistant Enterococcus infections in solid organ transplantation. Am J Transplant 2013;13 (Suppl. 4):59–67 [CrossRef][PubMed]
    [Google Scholar]
  4. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16:555–562 [CrossRef][PubMed]
    [Google Scholar]
  5. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009. Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1–45 [CrossRef][PubMed]
    [Google Scholar]
  6. FDA. FDA Warns of Increased Risk of Death with IV Antibacterial Tygacil (Tigecycline) and Approves New Boxed Warning. Silver Spring, MD:: U.S. Food and Drug Administration;; 2013
    [Google Scholar]
  7. Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 2012;54:S233–S238 [CrossRef][PubMed]
    [Google Scholar]
  8. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683–1693 [CrossRef][PubMed]
    [Google Scholar]
  9. Barnhill AE, Brewer MT, Carlson SA. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob Agents Chemother 2012;56:4046–4051 [CrossRef][PubMed]
    [Google Scholar]
  10. Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med 1989;87:44n–48n[PubMed]
    [Google Scholar]
  11. Gould CV, Fishman NO, Nachamkin I, Lautenbach E. Chloramphenicol resistance in vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use?. Infect Control Hosp Epidemiol 2004;25:138–145 [CrossRef][PubMed]
    [Google Scholar]
  12. Lynch C, Courvalin P, Nikaido H. Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemother 1997;41:869–871 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmmcr/10.1099/jmmcr.0.005172
Loading
/content/journal/jmmcr/10.1099/jmmcr.0.005172
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error